Abstract
Currently licensed vaccines have emanated from a relatively small number of production platforms. As shown in Table 9.1, these platforms have produced a large number of licensed products and are currently being used to develop a significant number of new vaccines that are currently under clinical evaluation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alimohammadian MH et al (2002) The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 21(3–4):174–180
Badger CV et al (2011) Development and application of a flow cytometric potency assay for DNA vaccines. Vaccine 29(39):6728–6735
Bagarazzi ML et al (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4(155):155ra138
Bahar K et al (1996) Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 14(5):489–495
Cleveland AA et al (2012) Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis 55(10):1352–1361
Edwards JE Jr (2012) Fungal cell wall vaccines: an update. J Med Microbiol 61(Pt 7):895–903
Epstein JE et al (2011a) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334(6055):475–480
Epstein JE et al (2011b) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science. www.sciencemag.org/cgi/content/full/science.1211548/DC1
Hennessey JP Jr, Shabb J (in progress) Structure-function analysis of the recombinant Als3 glycoprotein used as a vaccine antigen
Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9(10):776–788
Mahajan R et al (2008) A TaqMan reverse transcription polymerase chain reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products. Mol Biotechnol 40(1):47–57
Montgomery DL et al (1993) Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 12(9):777–783
Morrow MP, Yan J, Sardesai NY (2013) Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines 12(3):271–283
Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23(3):421–429
Seder RA et al (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341(6152):1359–1365
Ulmer JB et al (1994) Protective immunity by intramuscular injection of low doses of Influenza virus DNA vaccines. Vaccine 12(16):1541–1544
Ulmer JB et al (2012) RNA-based vaccines. Vaccine 30(30):4414–4418
US_Food_&_Drug_Administration (2007) Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091968.pdf
Wells L et al (2002) Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol Cell Proteomics 1(10):791–804
Wisplinghoff H et al (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39(3):309–317
World_Health_Organization (2007) Guidelines for assuring the quality and non-clinical safety evaluation of DNA vaccines: annex 1. http://www.who.int/biologicals/publications/trs/areas/vaccines/dna/Annex%201_DNA%20vaccines.pdf?ua=1
World_Health_Organization (2013a) Initiative for vaccine research: parasitic diseases. http://www.who.int/vaccine_research/diseases/soa_parasitic/en/index.html
World_Health_Organization (2013b) World malaria report. http://www.who.int/malaria/media/world_malaria_report_2013/en/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hennessey, J.P., Sardesai, N.Y. (2015). Vaccines in Research and Development: New Production Platforms and New Biomolecular Entities for New Needs. In: Nunnally, B., Turula, V., Sitrin, R. (eds) Vaccine Analysis: Strategies, Principles, and Control. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45024-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-662-45024-6_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45023-9
Online ISBN: 978-3-662-45024-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)